Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Nov;6(11):3272.
doi: 10.1002/hep4.1798. Epub 2021 Aug 24.

Letter to the Editor: Reply to Autoimmune Hepatitis and Coronavirus Disease 2019: Disease Outcomes and Tacrolimus Use

Cumali Efe  1 , Staffan Wahlin  2
Affiliations
Comment

Letter to the Editor: Reply to Autoimmune Hepatitis and Coronavirus Disease 2019: Disease Outcomes and Tacrolimus Use

Cumali Efe et al. Hepatol Commun. 2022 Nov.
No abstract available

PubMed Disclaimer

Comment on

  • Outcome of COVID-19 in Patients With Autoimmune Hepatitis: An International Multicenter Study.
    Efe C, Dhanasekaran R, Lammert C, Ebik B, Higuera-de la Tijera F, Aloman C, Rıza Calışkan A, Peralta M, Gerussi A, Massoumi H, Catana AM, Torgutalp M, Purnak T, Rigamonti C, Gomez Aldana AJ, Khakoo N, Kacmaz H, Nazal L, Frager S, Demir N, Irak K, Ellik ZM, Balaban Y, Atay K, Eren F, Cristoferi L, Batıbay E, Urzua Á, Snijders R, Kıyıcı M, Akyıldız M, Ekin N, Carr RM, Harputluoğlu M, Hatemi I, Mendizabal M, Silva M, Idilman R, Silveira M, Drenth JPH, Assis DN, Björnsson E, Boyer JL, Invernizzi P, Levy C, Schiano TD, Ridruejo E, Wahlin S. Efe C, et al. Hepatology. 2021 Jun;73(6):2099-2109. doi: 10.1002/hep.31797. Hepatology. 2021. PMID: 33713486 Free PMC article.
  • Letter to the Editor: Autoimmune Hepatitis and Coronavirus Disease 2019: Disease Outcomes and Tacrolimus Use.
    Ng AC. Ng AC. Hepatol Commun. 2021 Oct;5(10):1801-1802. doi: 10.1002/hep4.1750. Epub 2021 Jun 22. Hepatol Commun. 2021. PMID: 34222740 Free PMC article. No abstract available.

References

    1. Ng AC. Letter to the editor: autoimmune hepatitis and coronavirus disease 2019: disease outcomes and tacrolimus use. Hepatol Commun 2021. 10.1002/hep4.1750. - DOI - PMC - PubMed
    1. Efe C, Dhanasekaran R, Lammert C, Ebik B, Higuera‐de la Tijera F, Aloman C, et al. Outcome of COVID‐19 in patients with autoimmune hepatitis: an international multicenter study. Hepatology 2021;73:2099‐2109. - PMC - PubMed
    1. Belli LS, Fondevila C, Cortesi PA, Conti S, Karam V, Adam R, et al.; ELITA‐ELTR COVID‐19 Registry . Protective role of tacrolimus, deleterious role of age and comorbidities in liver transplant recipients with Covid‐19: results from the ELITA/ELTR multi‐center European study. Gastroenterology 2021;160:1151‐1163.e3. - PMC - PubMed
    1. Rabiee A, Sadowski B, Adeniji N, Perumalswami PV, Nguyen V, Moghe A, et al.; COLD Consortium . Liver injury in liver transplant recipients with coronavirus disease 2019 (COVID‐19): U.S. multicenter experience. Hepatology 2020;72:1900‐1911. - PMC - PubMed
    1. Nørgård BM, Nielsen J, Knudsen T, Nielsen RG, Larsen MD, Jølving LR, et al. Hospitalization for COVID‐19 in patients treated with selected immunosuppressant and immunomodulating agents, compared to the general population: a Danish cohort study. Br J Clin Pharmacol 2021;87:2111‐2120. - PubMed